<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15948">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00094458</url>
  </required_header>
  <id_info>
    <org_study_id>CR004804</org_study_id>
    <secondary_id>C0168T67</secondary_id>
    <nct_id>NCT00094458</nct_id>
  </id_info>
  <brief_title>Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC</brief_title>
  <official_title>Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor Ortho Biotech Services, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centocor Ortho Biotech Services, L.L.C.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of three different
      treatments for patients with Crohns disease who have not responded to previous treatment
      with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids.
      Patients will receive either infliximab (a drug used to treat autoimmune diseases) or
      azathioprine (an immunosuppressant or drug used to suppress the immune system) or a
      combination of both for up to 34 weeks. This research study will involve approximately 500
      patients. The main study involves up to 34 weeks (approximately 8 months). A study extension
      of an additional 20 weeks (approximately 5 months) is optional for patients who successfully
      complete the main study. A country-specific study extension of open label infliximab
      treatment for an additional 1 year is optional for patients who successfully complete the
      main study extension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohns disease is characterized by inflammation (the changes that happen when tissues in the
      body are injured) and ulceration (open sores) of the intestines. Crohns disease is treated
      with medications that decrease inflammation, and reduce diarrhea, abdominal pain and other
      symptoms of Crohns disease. In addition, Crohns disease can be treated with medications that
      suppress the immune system (the body system involved in inflammation and infections) or with
      surgery. This study will investigate the effectiveness of infliximab and azathioprine in the
      treatment of patients with moderate-to-severe Crohns disease. Infliximab is currently
      approved by the FDA for the treatment of both Crohns disease and rheumatoid arthritis.
      Azathioprine, which is an investigational drug, has not been approved by the FDA for the
      treatment of Crohns disease, but it is a well-established therapy that has been used for
      many years to treat Crohns disease. This study seeks to determine whether infliximab,
      azathioprine, or the combination of both drugs would be the most appropriate treatment for
      Crohns disease patients who have not responded well to certain drugs called 5-ASA drugs
      (e.g. Asacol, Pentasa, sulfasalazine) and/or require frequent treatment with
      corticosteroids. This research study will involve approximately 500 patients. Patients may
      participate in the main study for up to 34 weeks (approximately 8 months). During the main
      study, patients will be asked to visit the study center for 10 visits. If patients enroll
      into the extension of the study, the total time for participation may be up to 54 weeks
      (approximately 13 months). Patients enrolled in the Study Extension will be asked to visit
      the study center for an additional 5 visits. A country-specific (EU and Israel only),
      prospective, multi-center, open-label extension of the study will further evaluate the
      long-term safety and efficacy of scheduled maintenance therapy with infliximab in patients
      with Crohns Disease. Patients who have completed treatment through Week 50 in the SONIC main
      study and who, in the opinion of the investigator, would benefit from infliximab treatment
      may enter the open-label extension. Patients will be randomly assigned to one of three
      treatment groups (either infliximab plus placebo capsules, infliximab plus azathioprine, or
      azathioprine plus placebo infusions - there is no possibility of being assigned to placebo
      only in this trial - patients will receive one or both of these medications) at the
      beginning of the study. Oral medication will be taken daily. There are 5 infusion (which
      will be either infliximab or placebo) visits during the main study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Corticosteriod-free Clinical Remission</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) &lt; 150 in subjects who have not received any dose of systemic corticosteroids (prednisone or equivalent) for &gt;= 3 weeks and have not received budesonide at a dose &gt; 6mg/day for &gt;= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucosal Healing</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid-free Clinical Remission</measure>
    <time_frame>Week 50</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) &lt; 150 who have not received any dose of systemic corticosteroids (prednisone or equivalent) for &gt;= 3 weeks and have not received budesonide at a dose &gt; 6mg/day for &gt;= 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Over Time</measure>
    <time_frame>Weeks 26 and 50 (Remission was also measured at Weeks 2, 6, 10, 18, 34 and 42)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission is defined as a CDAI &lt; 150, compared to baseline (Week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Over Time</measure>
    <time_frame>Weeks 26 and 50 (Response was also measured at Weeks 2, 6, 10, 18, 34 and 42)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical response is defined as &gt;= 100 point decrease in CDAI, compared to baseline (Week 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Weeks 26 and 50 (Quality of Life was also assessed at Weeks 0, 2, 6, 10, 18, 34 and 42)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ is a 32-item questionnaire and the total IBDQ score can range from 32 (very poor) to 224 (perfect).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Corticosteroid Use</measure>
    <time_frame>Weeks 26 and 50 (Corticosteroid use was also measured at Weeks 0, 2, 6, 10, 18, 34 and 42)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Average daily dose of systemic corticosteroid concomitant medications(prednisone or equivalent)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>Week 52 of Open Label Extension</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical remission is defined as a CDAI &lt; 150</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab infusion; AZA placebo caps</intervention_name>
    <description>Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>infliximab (IFX) infusion; azathioprine (AZA) caps</intervention_name>
    <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab (IFX) placebo infusion; azathioprine (AZA) caps</intervention_name>
    <description>AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Crohns Disease for at least 6 weeks

          -  Moderate to severe disease activity (CDAI &gt;= 220 and &lt;=450)

          -  No history of azathioprine, 6-MP (6 Mercaptopurine), or biologic treatments

          -  Are either: Corticosteriod-dependent, OR considered for a 2nd (or greater) course of
             corticosteriod, OR 5-ASA failures, Or Budesonide failures

        Exclusion Criteria:

          -  History of abdominal surgery within the last 6 months

          -  Have an ostomy or stoma [An operation to create an opening from an area inside the
             body to the outside]

          -  Are pregnant, nursing, or planning pregnancy (both men and women)

          -  Serious simultaneous illness that could interfere with study participation

          -  Use of any investigational drug within 30 days

          -  Have a concomitant diagnosis or any history of congestive heart failure

          -  Weigh more than 140 kilograms (or 310 pounds)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor Ortho Biotech Services, L.L.C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor Ortho Biotech Services, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatfield</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hall In Tirol</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus C.</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amiens Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exohi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion- Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nicea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo N/A</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockhollm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livingston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockport</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.</citation>
    <PMID>20393175</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>October 19, 2004</firstreceived_date>
  <firstreceived_results_date>April 30, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>infliximab</keyword>
  <keyword>azathioprine</keyword>
  <keyword>Remicade</keyword>
  <keyword>SONIC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adjuvants, Immunologic</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azathioprine + Placebo</title>
          <description>Azathioprine (AZA) daily 2.5 mg/kg/day and placebo infliximab (IFX) infusions at weeks 0, 2, 6, 14, and 22</description>
        </group>
        <group group_id="P2">
          <title>Infliximab + Placebo</title>
          <description>IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules daily</description>
        </group>
        <group group_id="P3">
          <title>Infliximab + Azathioprine</title>
          <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170">5 subjects were randomized but did not receive any study medication</participants>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population: &gt;= 1 Dose of Drug</title>
              <participants_list>
                <participants group_id="P1" count="161">For safety analyses patients were analyzed based on the treatment they actually received.</participants>
                <participants group_id="P2" count="163">For safety analyses patients were analyzed based on the treatment they actually received.</participants>
                <participants group_id="P3" count="179">For safety analyses patients were analyzed based on the treatment they actually received.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusionary age &lt; 21</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect study treatment</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azathioprine + Placebo</title>
          <description>Azathioprine (AZA) daily 2.5 mg/kg/day and placebo infliximab (IFX) infusions at weeks 0, 2, 6, 14, and 22</description>
        </group>
        <group group_id="B2">
          <title>Infliximab + Placebo</title>
          <description>IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules daily</description>
        </group>
        <group group_id="B3">
          <title>Infliximab + Azathioprine</title>
          <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="169"/>
                <measurement group_id="B3" value="169"/>
                <measurement group_id="B4" value="508"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35.0" lower_limit="26" upper_limit="43"/>
                <measurement group_id="B2" value="35.0" lower_limit="26" upper_limit="46"/>
                <measurement group_id="B3" value="34.0" lower_limit="26" upper_limit="45"/>
                <measurement group_id="B4" value="34.0" lower_limit="26" upper_limit="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="80"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="81"/>
                <measurement group_id="B4" value="246"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="90"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="88"/>
                <measurement group_id="B4" value="262"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corticosteriod-free Clinical Remission</title>
        <description>Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) &lt; 150 in subjects who have not received any dose of systemic corticosteroids (prednisone or equivalent) for &gt;= 3 weeks and have not received budesonide at a dose &gt; 6mg/day for &gt;= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse).</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine + Placebo</title>
            <description>Azathioprine (AZA) daily 2.5 mg/kg/day and placebo infliximab (IFX) infusions at weeks 0, 2, 6, 14, and 22</description>
          </group>
          <group group_id="O2">
            <title>Infliximab + Placebo</title>
            <description>IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules daily</description>
          </group>
          <group group_id="O3">
            <title>Infliximab + Azathioprine</title>
            <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="170"/>
                  <measurement group_id="O2" value="169"/>
                  <measurement group_id="O3" value="169"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Corticosteriod-free Clinical Remission</title>
            <description>Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) &lt; 150 in subjects who have not received any dose of systemic corticosteroids (prednisone or equivalent) for &gt;= 3 weeks and have not received budesonide at a dose &gt; 6mg/day for &gt;= 3 weeks. The total CDAI score ranges from 0 - 600. The lower the CDAI score, the better (i.e., 0 is better and 600 is worse).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30.0"/>
                  <measurement group_id="O2" value="44.4"/>
                  <measurement group_id="O3" value="56.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.022</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucosal Healing</title>
        <description>Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis population for mucosal healing was per protocol. All subjects with lesions at Baseline (Week 0) and an Endoscopy at Week 26 were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine + Placebo</title>
            <description>Azathioprine (AZA) daily 2.5 mg/kg/day and placebo infliximab (IFX) infusions at weeks 0, 2, 6, 14, and 22</description>
          </group>
          <group group_id="O2">
            <title>Infliximab + Placebo</title>
            <description>IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules daily</description>
          </group>
          <group group_id="O3">
            <title>Infliximab + Azathioprine</title>
            <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="109"/>
                  <measurement group_id="O2" value="93"/>
                  <measurement group_id="O3" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mucosal Healing</title>
            <description>Complete absence of mucosal ulcerations in the colon and terminal ileum as assessed by video endoscopy</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16.5"/>
                  <measurement group_id="O2" value="30.1"/>
                  <measurement group_id="O3" value="43.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.023</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.055</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>The P-Value is from a CMH test stratified by duration of Crohn’s disease and corticosteroid treatment at Baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Remission</title>
        <description>Clinical remission is defined as a CDAI &lt; 150</description>
        <time_frame>Week 52 of Open Label Extension</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2010</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid-free Clinical Remission</title>
        <description>Corticosteroid-free clinical remission is defined as a Crohn's Disease Activity Index (CDAI) &lt; 150 who have not received any dose of systemic corticosteroids (prednisone or equivalent) for &gt;= 3 weeks and have not received budesonide at a dose &gt; 6mg/day for &gt;= 3 weeks</description>
        <time_frame>Week 50</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>11/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Remission Over Time</title>
        <description>Clinical remission is defined as a CDAI &lt; 150, compared to baseline (Week 0)</description>
        <time_frame>Weeks 26 and 50 (Remission was also measured at Weeks 2, 6, 10, 18, 34 and 42)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>11/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Over Time</title>
        <description>Clinical response is defined as &gt;= 100 point decrease in CDAI, compared to baseline (Week 0).</description>
        <time_frame>Weeks 26 and 50 (Response was also measured at Weeks 2, 6, 10, 18, 34 and 42)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>11/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of life as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ is a 32-item questionnaire and the total IBDQ score can range from 32 (very poor) to 224 (perfect).</description>
        <time_frame>Weeks 26 and 50 (Quality of Life was also assessed at Weeks 0, 2, 6, 10, 18, 34 and 42)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>11/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Corticosteroid Use</title>
        <description>Average daily dose of systemic corticosteroid concomitant medications(prednisone or equivalent)</description>
        <time_frame>Weeks 26 and 50 (Corticosteroid use was also measured at Weeks 0, 2, 6, 10, 18, 34 and 42)</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>11/2009</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Azathioprine + Placebo</title>
          <description>Azathioprine (AZA) daily 2.5 mg/kg/day and placebo infliximab (IFX) infusions at weeks 0, 2, 6, 14, and 22</description>
        </group>
        <group group_id="E2">
          <title>Infliximab + Placebo</title>
          <description>IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules daily</description>
        </group>
        <group group_id="E3">
          <title>Infliximab + Azathioprine</title>
          <description>AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39"/>
                <counts group_id="E2" subjects_affected="26"/>
                <counts group_id="E3" subjects_affected="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Enterocolonic fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Small intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Crush injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dyshidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132"/>
                <counts group_id="E2" subjects_affected="137"/>
                <counts group_id="E3" subjects_affected="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Centocor Ortho Biotech Services, L.L.C.</organization>
      <phone>215 325-7405</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
